$DMTKQ
DermTech Inc Stock $dmtkq

$dmtkq Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000165194424000047 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue		$3.845M
YoY Change		10.58%
Cost Of Revenue		$3.132M
YoY Change		-18.03%
Gross Profit		$713.0K
YoY Change		-307.27%
Gross Profit Margin		18.54%
Selling, General & Admin		$17.96M
YoY Change		-34.21%
% of Gross Profit		2518.23%
Research & Development		$3.266M
YoY Change		-25.92%
% of Gross Profit		458.06%
Depreciation & Amortization		$490.0K
YoY Change		5.15%
% of Gross Profit		68.72%
Operating Expenses		$21.22M
YoY Change		-33.06%
Operating Profit		-$20.51M
YoY Change		-36.0%
Interest Expense		$498.0K
YoY Change		-36.32%
% of Operating Profit
Other Income/Expense, Net		$498.0K
YoY Change		-35.74%
Pretax Income		-$20.01M
YoY Change		-36.01%
Income Tax
% Of Pretax Income
Net Earnings		-$20.00M
YoY Change		-36.04%
Net Earnings / Revenue		-520.16%
Basic Earnings Per Share		-$0.58
Diluted Earnings Per Share		-$0.58
COMMON SHARES
Basic Shares Outstanding	34.96M shares	34.62M shares
Diluted Shares Outstanding		34.71M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$38.98M
YoY Change		-62.8%
Cash & Equivalents		$27.60M
Short-Term Investments		$11.40M
Other Short-Term Assets		$651.0K
YoY Change		-1.36%
Inventory		$831.0K
Prepaid Expenses
Receivables		$2.497M
Other Receivables		$0.00
Total Short-Term Assets		$44.20M
YoY Change		-60.67%
LONG-TERM ASSETS
Property, Plant & Equipment		$4.498M
YoY Change		-28.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$3.467M
YoY Change		1963.69%
Total Long-Term Assets		$58.77M
YoY Change		-9.21%
TOTAL ASSETS
Total Short-Term Assets		$44.20M
Total Long-Term Assets		$58.77M
Total Assets		$103.0M
YoY Change		-41.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.913M
YoY Change		13.87%
Accrued Expenses		$1.943M
YoY Change		-59.58%
Deferred Revenue		$200.0K
YoY Change		0.0%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$17.00K
YoY Change		-82.47%
Total Short-Term Liabilities		$12.52M
YoY Change		-22.43%
LONG-TERM LIABILITIES
Long-Term Debt		$34.00K
YoY Change		-30.61%
Other Long-Term Liabilities		$50.42M
YoY Change		-6.09%
Total Long-Term Liabilities		$50.46M
YoY Change		-6.11%
TOTAL LIABILITIES
Total Short-Term Liabilities		$12.52M
Total Long-Term Liabilities		$50.46M
Total Liabilities		$62.98M
YoY Change		-9.88%
SHAREHOLDERS EQUITY
Retained Earnings		-$443.9M
YoY Change		25.29%
Common Stock		$483.8M
YoY Change		4.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$39.99M
YoY Change
Total Liabilities & Shareholders Equity		$103.0M
YoY Change		-41.86%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income		-$20.00M
YoY Change		-36.04%
Depreciation, Depletion And Amortization		$490.0K
YoY Change		5.15%
Cash From Operating Activities		-$17.10M
YoY Change		-22.37%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$7.834M
YoY Change		-205.34%
Cash From Investing Activities		$7.834M
YoY Change		-195.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$122.0K
YoY Change		-86.68%
NET CHANGE
Cash From Operating Activities		-$17.10M
Cash From Investing Activities		$7.834M
Cash From Financing Activities		$122.0K
Net Change In Cash		-$9.163M
YoY Change		-68.73%
FREE CASH FLOW
Cash From Operating Activities		-$17.10M
Capital Expenditures		$0.00
Free Cash Flow		-$17.10M
YoY Change		-24.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001651944
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	DERMTECH, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2870849
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	12340 El Camino Real
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2024Q1	dei	City Area Code CityAreaCode	858
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	450-4222
CY2024Q1	dei	Trading Symbol TradingSymbol	DMTK
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34962994	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27579000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36741000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11400000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19123000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2497000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2584000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	831000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1004000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1892000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2300000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	61752000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4498000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4988000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50806000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	51722000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3467000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3468000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	485000	usd
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q1	us-gaap	Assets Current AssetsCurrent	44199000	usd
CY2024Q1	us-gaap	Assets Assets	102970000	usd
CY2023Q4	us-gaap	Assets Assets	121930000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1913000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1484000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5248000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6664000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1943000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2017000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	203000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	196000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3194000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3069000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	17000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	17000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12518000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13447000	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	34000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50424000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51270000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	62976000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	64755000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34962994	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34962994	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34524677	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34524677	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	483752000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	480929000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	184000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	178000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443945000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-423935000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	39994000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57175000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102970000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121930000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3845000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3477000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	3132000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	3821000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	713000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-344000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7817000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15417000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3266000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4409000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10138000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11875000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	21221000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	31701000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20508000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32045000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	498000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	782000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	498000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	775000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20010000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31270000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34706491	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34706491	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30557216	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30557216	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20010000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31270000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	485000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20004000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30785000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	57175000	usd
CY2024Q1	dmtk	Stock Issued During Period Value Employee Stock Purchase Plan Net Of Shares Withheld For Employee Taxes StockIssuedDuringPeriodValueEmployeeStockPurchasePlanNetOfSharesWithheldForEmployeeTaxes	-32000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	158000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2697000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20010000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	39994000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	132353000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	270000	usd
CY2023Q1	dmtk	Stock Issued During Period Value Employee Stock Purchase Plan Net Of Shares Withheld For Employee Taxes StockIssuedDuringPeriodValueEmployeeStockPurchasePlanNetOfSharesWithheldForEmployeeTaxes	92000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	576000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4736000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31270000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	107242000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-20010000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-31270000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	490000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	466000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	916000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1207000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2697000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4736000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	104000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	29000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-87000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-482000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-173000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-183000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-407000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1592000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-721000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-227000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	362000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1169000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1416000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-338000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17119000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22028000	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16481000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7834000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9044000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	757000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7834000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8194000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270000	usd
CY2024Q1	dmtk	Proceeds Payments From Stock Plans Net Of Shares Withheld For Employee Taxes ProceedsPaymentsFromStockPlansNetOfSharesWithheldForEmployeeTaxes	-32000	usd
CY2023Q1	dmtk	Proceeds Payments From Stock Plans Net Of Shares Withheld For Employee Taxes ProceedsPaymentsFromStockPlansNetOfSharesWithheldForEmployeeTaxes	92000	usd
CY2024Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	158000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	576000	usd
CY2024Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	4000	usd
CY2023Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	22000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	916000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9163000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-29306000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40209000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81245000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	31046000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51939000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27579000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48438000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	3467000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	3501000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31046000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51939000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	5000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	usd
CY2024Q1	dmtk	Change In Unrealized Gain Loss On Available For Sale Marketable Securities ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities	-77000	usd
CY2023Q1	dmtk	Change In Unrealized Gain Loss On Available For Sale Marketable Securities ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities	485000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-443900000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27600000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11400000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-20000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17100000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates <div style="margin-top:9pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the amounts of revenues and expenses reported during the period. On an ongoing basis, management evaluates these estimates and judgments, including but not limited to those related to test revenue, stock-based compensation, short-term marketable securities, accounts receivable, accrued bonus, warrant liability, right-of-use (“ROU”) assets and the realization of deferred tax assets. Actual results may differ from those estimates.</span></div>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and available-for-sale marketable securities. The Company invests its cash balances in major financial institutions that it believes have high credit quality and are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash deposits might exceed FDIC insurance limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk.
CY2024Q1	dmtk	Number Of Revenue Streams NumberOfRevenueStreams	2	revenuestream
CY2024Q1	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	73000	usd
CY2023Q1	dmtk	Revenue Performance Obligation Satisfied Variable Consideration Update Increase Decrease In Revenue RevenuePerformanceObligationSatisfiedVariableConsiderationUpdateIncreaseDecreaseInRevenue	-500000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3845000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3477000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	200000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	200000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4236000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6243000	shares
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11318000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	106000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	24000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11400000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	18965000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	208000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	50000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19123000	usd
CY2024Q1	dmtk	Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months	11400000	usd
CY2023Q4	dmtk	Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months	19100000	usd
CY2023Q4	dmtk	Credit Losses CreditLosses	0	usd
CY2024Q1	dmtk	Credit Losses CreditLosses	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	3092000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	11000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4370000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	13000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	7462000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	24000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	2587000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	9000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	5566000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	41000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	8153000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	50000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1241000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1719000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	651000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	581000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1892000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2300000	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6055000	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6100000	usd
CY2024Q1	dmtk	Computer Equipment Gross ComputerEquipmentGross	831000	usd
CY2023Q4	dmtk	Computer Equipment Gross ComputerEquipmentGross	831000	usd
CY2024Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1248000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1248000	usd
CY2024Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	604000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	604000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8738000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8783000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4240000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3795000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4498000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4988000	usd
CY2024Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2350000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3534000	usd
CY2024Q1	dmtk	Accrued Bonus And Deferred Compensation Current AccruedBonusAndDeferredCompensationCurrent	2898000	usd
CY2023Q4	dmtk	Accrued Bonus And Deferred Compensation Current AccruedBonusAndDeferredCompensationCurrent	3130000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5248000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6664000	usd
CY2024Q1	dmtk	Accrued Consulting Services Current AccruedConsultingServicesCurrent	365000	usd
CY2023Q4	dmtk	Accrued Consulting Services Current AccruedConsultingServicesCurrent	262000	usd
CY2024Q1	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	1008000	usd
CY2023Q4	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	1008000	usd
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	93000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	10000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	477000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	737000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1943000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2017000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2697000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4736000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13600000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M20D
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001651944-24-000047-index-headers.html	Edgar Link	pending
0001651944-24-000047-index.html	Edgar Link	pending
0001651944-24-000047.txt	Edgar Link	pending
0001651944-24-000047-xbrl.zip	Edgar Link	pending
dmtk-20240330xex311.htm	Edgar Link	pending
dmtk-20240330xex312.htm	Edgar Link	pending
dmtk-20240330xex321.htm	Edgar Link	pending
dmtk-20240331.htm	Edgar Link	pending
dmtk-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
dmtk-20240331_cal.xml	Edgar Link	unprocessable
dmtk-20240331_def.xml	Edgar Link	unprocessable
dmtk-20240331_lab.xml	Edgar Link	unprocessable
dmtk-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dmtk-20240331_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMTKQ
DermTech Inc Stock $dmtkq

2024 Q2 Form 10-Q Financial Statement

#000165194424000047 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMTKQ DermTech Inc Stock $dmtkq

2024 Q2 Form 10-Q Financial Statement

#000165194424000047 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMTKQ
DermTech Inc Stock $dmtkq